Role of PARP inhibitors in prostate cancer

DSB may develop as a result of DNA replication if SSB goes unrepaired [17]. Because replication forks can break when they come into contact with a SSB, homologous recombination is an essential mechanism for repairing replication forks and preventing fork collapse [18]. CURRENT APPLICATIONS AND STUDY RESULTS OF PARP INHIBITORS Olaparib In December 2014, olaparib (Lynparza, Astra Zeneca AB, and Merck) was approved in the European Union and the United States for the treatment of advanced ovarian cancer and breast cancer with BRCA1/2 gene mutations [25]. Patients with deleterious or suspected deleterious gBRCAm, HER2-negative (no human epidermal growth factor receptor type 2) metastatic breast cancer who have received chemotherapy in the neoadjuvant, adjuvant, or metastatic setting are eligible for treatment with Lynparza [26]. [...]the median overall survival (0S) was 18.5 months for patients in the olaparib arm compared to 15.1 months for those in the control group [28].